



ASX / MEDIA RELEASE

8 March 2011

Milestone EEG contract win to equip the new & internationally acclaimed Royal Children's Hospital, Melbourne

Melbourne, Australia, March 8, 2011 -- Compumedics Limited (ASX:CMP) today announced another significant milestone by being awarded the contract to supply EEG equipment for the Neuroscience Centre at the new Royal Children's Hospital Melbourne (RCH), which opens in late 2011. Upon opening, the RCH's pediatric epilepsy / EEG facility will be the largest in the Southern Hemisphere. The contract to deliver the latest Compumedics EEG technologies includes the new Compumedics NEUVO® LTM EEG, Grael®HD and Siesta®802 wireless systems. The EEG systems are to be used for routine clinical EEG and surgical monitoring. This purchase represents another major milestone in Compumedics' entry into the global \$250 million LTM/Neurophysiology market.

The sale, with an order value of more than AUD500K, will deliver Compumedics' latest EEG technologies into the RCH. The supplied NEUVO® LTM EEG systems can record 64 individual channels of high-density EEG data on a single patient for days or weeks at a time. The Grael®HD system provides high definition EEG signals and the Siesta®802 remains the industry's most compact wireless EEG recording device. Compumedics' digital amplifier technology and breadth of EEG diagnostic offerings is superior to all other competitors and provides Compumedics with a unique point of differentiation. Compumedics' product offerings provide higher quality brain recordings and more precise brain analysis, improving patient outcomes.

The RCH Melbourne is one of the world's great children's hospitals. It is internationally recognised as a leading centre of paediatric treatment, teaching and research. The RCH is the major specialist paediatric hospital in Victoria and its care extends to children from Tasmania, southern New South Wales and other states around Australia and overseas.

The RCH Epilepsy Program states that "1 in 20 (5%) children will have a seizure of some form during childhood. About 1 in 200 (0.5%) children have epilepsy."

For personal use only

Cameron Charles, Compumedics' Australian EEG Business Manager, said,

"This sale which includes Compumedics' latest EEG solutions Grael®HD, NEUVO®LTM and Siesta®802 will provide the RCH with the best EEG technologies available on the market today and will be used to provide better care of children with epilepsy and neurological problems."

Compumedics has made significant investments in product development, targeting the neuro-diagnostics market, to leverage its expertise in high-end amplifier design and physiologic signal processing.

Dr. David Burton, Chairman and Chief Executive Officer of Compumedics Group commented,

"This contract is another important milestone for our Company. It reinforces our commitment to our customers and the patients under their care. The world-class Royal Children's Hospital installation establishes a new and innovative standard for long term EEG monitoring. This project further underpins our strategy to grow our business across this important but relatively new market sector for Compumedics."

About Compumedics

Compumedics Limited, was founded in **1987** by current Chairman/CEO Dr. David Burton and today is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In **1987** Compumedics established Asia Pacific's first fully computerized sleep laboratory. Compumedics holds 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian marketplaces for its sleep, neurological, and Doppler blood-flow diagnostic monitoring devices. In **1995** the company was selected to supply equipment to the US Sleep Heart Health Study, the world's largest sleep study of its kind, with over 8,000 participants scheduled by 2008. With headquarters in Melbourne, Australia and offices in the United States, and Europe its products are distributed in over 50 countries. In **1998** Compumedics was awarded the overall Australian Exporter of the Year. In **2000** Compumedics was listed on the Australian Stock Exchange. In **2002**, Compumedics acquired US-based **Neuroscan** - the world's leading supplier of instruments for brain research. In the US - the world's largest medical device market - Neuroscan holds around 90% of the market for brain-research products. In **2003** Compumedics was awarded the Frost & Sullivan Award for Market Expansion Strategy. In **2004**, Compumedics acquired Germany-based **DWL Elektronische GmbH**, enabling Compumedics to expand its global operations into the neurovascular and cardio-vascular diagnostic fields. In **2006**, Compumedics was awarded the Frost and Sullivan Technology Leadership award for its innovative Somté® recorder product. In **2007**, Compumedics and its Chairman were inducted into the Victorian Manufacturing Hall of Fame. In **2008** the DWL division received a top 100 German Innovation award. With 20,000 systems installed globally across the finest hospital, universities and clinics Compumedics sales have grown more than 4-fold from \$9 million (1999) to \$39 million (2008). In **2009** Compumedics was awarded a design award for its GRAEL® PSG/EEG premium laboratory-based product. In **2010** Compumedics was recognized by the Australian Innovation Government and Industry body as one of Australia's Top 100 Health Innovators through its' world leading devices for sleep diagnostics. **For further background please visit:** www.compumedics.com <http://www.compumedics.com>

For further information please contact:

Compumedics Chairman/CEO: Dr. David Burton 61-3-8420-7300;
dburton@compumedics.com.au

Bourse Communications: Mr. Rod North T: 03 9510 8309 M: 0408 670 706
E: rod@boursecommunications.com.au **Investors:** CMP.ASX (ASX.COM)